SHC · Insider Trading
Sotera Health Company Common Stock
Every open-market purchase and sale reported by SHC officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-19 | Michael B. Petras Jr. | Executive Chairman | Sell | −1,144,515 | −$21.17M |
| 2026-08-11 | Michael P Rutz | President of Sterigenics | Sell | −150,000 | −$2.83M |
| 2026-08-07 | Jonathan M. Lyons | Sr. Vice President, CFO | F | −11,316 | −$203.46K |
| 2026-08-07 | Jonathan M. Lyons | Sr. Vice President, CFO | F | −11,316 | −$203.46K |
| 2026-05-27 | David E. Wheadon | Director | A | +14,970 | — |
| 2026-05-27 | Christopher Simon | Director | A | +14,970 | — |
| 2026-05-27 | Ruoxi Chen | Director | A | +14,970 | — |
| 2026-05-27 | Vincent K Petrella | Director | A | +14,970 | — |
| 2026-05-27 | James Neary | Director | A | +14,970 | — |
| 2026-05-27 | Karen Flynn | Director | A | +14,970 | — |
| 2026-05-27 | Sean Laurence Cunningham | Director | A | +14,970 | — |
| 2026-05-27 | Kenneth D. Krause | Director | A | +14,970 | — |
| 2026-05-27 | Richard G Kyle | Director | A | +14,970 | — |
| 2026-05-27 | Alton Shader | Chief Executive Officer | A | +579,573 | — |
| 2026-05-27 | Ann R. Klee | Director | A | +14,970 | — |
| 2026-05-15 | GTCR FUND XI/A LP | Director | Sell | −63,676,505 | −$965.85M |
| 2026-05-15 | Warburg Pincus XI Partners, L.P. | Director | Sell | −191,029,520 | −$2.90B |
| 2026-05-15 | WARBURG PINCUS LLC | Director | Sell | −152,823,616 | −$2.32B |
| 2026-04-02 | Alexander Dimitrief | Former SVP, GC and Sec. | F | −7,941 | −$113.87K |
| 2026-03-10 | GTCR CO-INVEST XI LP | Director | Sell | −50,000,000 | −$763.50M |
| 2026-03-10 | Warburg Pincus XI, L.P. | Director | Sell | −150,000,000 | −$2.29B |
| 2026-03-10 | Warburg Pincus Partners GP LLC | Director | Sell | −120,000,000 | −$1.83B |
| 2026-03-04 | Michael P Rutz | President of Sterigenics | MIXED | +34,075 | −$409.22K |
| 2026-03-04 | Jonathan M. Lyons | Sr. Vice President, CFO | MIXED | +39,018 | −$608.94K |
| 2026-03-04 | Alexander Dimitrief | SVP, General Counsel and Sec. | MIXED | −14,744 | −$502.12K |
| 2026-03-04 | Michael B. Petras Jr. | Chairman & CEO | MIXED | +139,637 | −$3.03M |
| 2026-02-13 | Richard G Kyle | Director | — | — | — |
| 2025-12-10 | Michael B. Petras Jr. | Chairman & CEO | Sell | −750,000 | −$12.34M |
| 2025-12-05 | GTCR FUND XI/A LP | Director | Sell | −32,400,000 | −$529.09M |
| 2025-12-05 | Warburg Pincus XI-C, LLC | Director | Sell | −77,760,000 | −$1.27B |
| 2025-12-05 | Warburg Pincus Partners GP LLC | Director | Sell | −77,760,000 | −$1.27B |
| 2025-11-12 | Warburg Pincus XI Partners, L.P. | Director | Sell | −180,000,000 | −$2.82B |
| 2025-11-12 | Warburg Pincus XI-C, LLC | Director | Sell | −144,000,000 | −$2.25B |
| 2025-11-12 | GTCR FUND XI/C LP | Director | Sell | −60,000,000 | −$939.06M |
| 2025-09-09 | GTCR CO-INVEST XI LP | Director | Sell | −40,000,000 | −$604.44M |
| 2025-09-09 | Warburg Pincus XI, L.P. | Director | Sell | −120,000,000 | −$1.81B |
| 2025-09-09 | Warburg Pincus XI-C, LLC | Director | Sell | −96,000,000 | −$1.45B |
| 2025-08-26 | Michael P Rutz | President of Sterigenics | Sell | −126,611 | −$2.07M |
| 2025-08-07 | Jonathan M. Lyons | Sr. Vice President, CFO | F | −11,508 | −$128.77K |
| 2025-05-27 | Christopher Simon | Director | A | +19,132 | — |
| 2025-05-27 | Ruoxi Chen | Director | A | +19,132 | — |
| 2025-05-27 | Sean Laurence Cunningham | Director | A | +19,132 | — |
| 2025-05-27 | Ann R. Klee | Director | A | +19,132 | — |
| 2025-05-27 | Constantine S Mihas | Director | A | +19,132 | — |
| 2025-05-27 | James Neary | Director | A | +19,132 | — |
| 2025-05-27 | Vincent K Petrella | Director | A | +19,132 | — |
| 2025-05-27 | David E. Wheadon | Director | A | +19,132 | — |
| 2025-05-27 | Robert Brown Knauss | Director | A | +19,132 | — |
| 2025-05-27 | Karen Flynn | Director | A | +19,132 | — |
| 2025-03-04 | Alexander Dimitrief | SVP, General Counsel and Sec. | MIXED | +47,842 | −$102.39K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Warburg Pincus XI-C, LLC | Director | 34,102,952 | $606.01M |
| GTCR FUND XI/C LP | Director | 29,215,301 | $519.16M |
| Warburg Pincus Partners GP LLC | Director | 19,102,952 | $339.46M |
| Warburg Pincus XI, L.P. | Director | 19,102,952 | $339.46M |
| GTCR CO-INVEST XI LP | Director | 12,735,301 | $226.31M |
| Michael B. Petras Jr. | Executive Chairman | 4,367,305 | $77.61M |
| Alton Shader | Chief Executive Officer | 375,939 | $6.68M |
| Michael P Rutz | President of Sterigenics | 334,279 | $5.94M |
| Alexander Dimitrief | Former SVP, GC and Sec. | 312,040 | $5.54M |
| Jonathan M. Lyons | Sr. Vice President, CFO | 217,304 | $3.86M |
| Ann R. Klee | Director | 140,926 | $2.50M |
| James Neary | Director | 95,751 | $1.70M |
| Vincent K Petrella | Director | 95,751 | $1.70M |
| Ruoxi Chen | Director | 95,751 | $1.70M |
| Sean Laurence Cunningham | Director | 95,751 | $1.70M |
| David E. Wheadon | Director | 89,882 | $1.60M |
| Constantine S Mihas | Director | 80,781 | $1.44M |
| Robert Brown Knauss | Director | 54,933 | $976.16K |
| Karen Flynn | Director | 54,191 | $962.97K |
| Christopher Simon | Director | 34,102 | $605.99K |
| Kenneth D. Krause | Director | 14,970 | $266.02K |
| Richard G Kyle | Director | 14,970 | $266.02K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the SHC quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.